07 July 2018
: Case report 
A Suspected Case of Hydralazine-Induced Hepatotoxicity: A Case Report and Review of Literature
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Unexpected drug reaction, Rare disease
Munish Sharma1ABCDEFG*, Milkeesso Foge2EF, Daniel Mascarenhas3ADEFDOI: 10.12659/AJCR.909279
Am J Case Rep 2018; 19:800-803
Abstract
BACKGROUND: Hydralazine is an effective antihypertensive agent but may rarely have devastating hepatotoxic effects that are extremely variable, thus making the diagnosis difficult.
CASE REPORT: We report the case of a 74-year-old male patient who had transaminitis after being started on hydralazine by his cardiologist for poorly controlled hypertension. He had extreme dizziness, nausea, and weakness, which all resolved after discontinuation of hydralazine, and liver function test results also dramatically improved.
CONCLUSIONS: It is imperative that clinicians be aware of the possible hepatotoxicity of hydralazine and its clinical features so that the medication can be promptly discontinued to help promote liver recovery. This case report will add to the current literature about such infrequent cases of hydralazine-induced hepatotoxicity.
Keywords: Alanine Transaminase, Antihypertensive Agents, Hydralazine
In Press
05 Mar 2024 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.942032
06 Mar 2024 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.942937
12 Mar 2024 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.943244
13 Mar 2024 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.943275
Most Viewed Current Articles
07 Mar 2024 : Case report
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
10 Jan 2022 : Case report 
DOI :10.12659/AJCR.935263
Am J Case Rep 2022; 23:e935263
19 Jul 2022 : Case report
DOI :10.12659/AJCR.936128
Am J Case Rep 2022; 23:e936128
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250